Next Generation Acylfulvene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FDA has granted orphan drug designation to LP-284 for use in the treatment of patients with high-grade B-cell lymphoma harboring MYC and BCL2 rearrangements.

United statesLantern pharma incLantern pharmaLp 284High gradeb cell lymphomaBlood cancerPrecision medMyc and bcl2 rearrangementsOrphan drug designationNext generation acylfulvene